Drug Profile
Esketamine - Amneal Laboratories
Alternative Names: IPX 237; IPX237-C0001; IPX237-C0002; IPX237-L0001Latest Information Update: 26 Nov 2021
Price :
$50
*
At a glance
- Originator IMPAX Laboratories
- Developer Amneal Pharmaceuticals
- Class Analgesics; Antidepressants; Chlorobenzenes; Cyclohexanones; General anaesthetics; Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Undefined(In volunteers) in Australia (PO, Capsule)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Undefined(In volunteers) in Australia (Sublingual, Paste)
- 07 May 2018 Amneal Pharmaceuticals and Impax Laboratories completed their business combination to form Amneal Pharmaceuticals